Novo Nordisk Expands Insulin Manufacturing Facility in Denmark

Novo Nordisk is investing 400 million Danish kroner (more than 65 million USD) in a 500-m² extension of what the company notes is the world's largest insulin production plant in Kalundborg, Denmark. Groundbreaking for the expansion took place on July 4, 2016 and is expected to be completed at the end of 2018.

"The expansion of our production plant highlights our ambition to continue strengthening our presence in Kalundborg. The new facilities will give us greater flexibility and enable the installation of equipment that will enhance efficiency and increase the long-term production capacity of the plant," said Michael Hallgren, senior vice-president and head of production in Kalundborg, in a press release.

Established in 1969, the Kalundborg production site today covers a total area of 1.1 million m². The facility produces 50% of the world's insulin as well as a range of biopharmaceutical products.